Carcinoma, renal cell Trials in New York, United States
Conditions / Carcinoma, renal cell / New York, United States
Clinical trials for Carcinoma, renal cell investigate a range of treatment strategies and patient populations.
35 total trials for this combination
Showing top 10 of 35 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00065468 | Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma | COMPLETED | PHASE3 |
| NCT00111020 | Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma | COMPLETED | PHASE3 |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | APPROVED_FOR_MARKETING | — |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00073307 | Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer | COMPLETED | PHASE3 |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | TERMINATED | PHASE1 |
| NCT00720941 | Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma | COMPLETED | PHASE3 |
| NCT05239728 | A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02627963 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | COMPLETED | PHASE3 |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |